HanchorBio Advances HCB101 Global Partnering Opportunities at BIO-Europe 2026
Expanding clinical evidence and macrophage-directed combination potential open new pathways for global collaboration.
TAIPEI, SHANGHAI, and SAN FRANCISCO — October 27, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany.
Since BIO-Europe Spring, HanchorBio has achieved significant milestones, including its Taiwan Stock Exchange Innovation Board listing, expanding HCB101 clinical evidence, U.S. FDA feedback supporting a randomized registrational development strategy in second-line gastric cancer, U.S. IND clearance for HCB303, and strategic collaborations with InxMed and Aston Sci.
These advances position HanchorBio to pursue a broader opportunity: developing HCB101 as a potential macrophage-directed immunotherapy backbone while expanding global partnerships and the value of its FBDB™ platform.
HCB101: From Clinical Evidence to Global Franchise Potential
HCB101, HanchorBio’s lead engineered SIRPα–IgG4 Fc fusion protein, is designed to restore macrophage-mediated tumor clearance through CD47–SIRPα checkpoint blockade while reducing red blood cell binding.
In second-line gastric/gastroesophageal junction (GC/GEJ) cancer, an October 2026 clinical update reported a preliminary 50.0% objective response rate (11/22) and 100% disease control rate with HCB101 plus ramucirumab and paclitaxel. U.S. FDA feedback supported the proposed randomized Phase 2b dose-optimization lead-in followed by a confirmatory Phase 3 trial with overall survival as the primary endpoint.
Beyond gastric cancer, preliminary clinical observations across colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and triple-negative breast cancer (TNBC), together with encouraging preclinical combination findings, support further investigation of HCB101 across complementary treatment approaches.
Approaches under consideration include tumor-targeting antibodies, antibody-drug conjugates (ADCs), PD-1/VEGF bispecifics, therapeutic cancer vaccines, and tumor microenvironment-modulating agents.
HanchorBio believes HCB101’s potential value extends beyond any single indication, with opportunities to build a broader immunotherapy program through scientifically validated combinations and global development partnerships.
From Scientific Innovation to Strategic Partnerships
HanchorBio is advancing a partner-enabled development strategy that combines HCB101’s macrophage-directed mechanism with complementary therapeutic technologies.
Recent collaborations with InxMed, involving FAK inhibition, and Aston Sci., involving therapeutic cancer vaccines, reflect the Company’s expanding approach to combination development.
At BIO-Europe, HanchorBio plans to continue ongoing scientific discussions and explore potential new collaborations focused on preclinical evaluation, clinical co-development, drug supply, joint research, and strategic licensing.
The objective is to translate complementary science into defined development programs, supported by appropriate experimental evidence, clinical strategies, and shared development capabilities.
FBDB™: Extending Innovation Beyond HCB101
HCB101 provides a clinical foundation for HanchorBio’s proprietary Fc-Based Designer Biologics (FBDB™) platform, which integrates Fc engineering and multifunctional molecular design to address complementary immune pathways.
The Company’s expanding pipeline includes:
- HCB303, a SIRPα × PD-L1 × TIGIT trispecific immunotherapy that received U.S. FDA IND clearance in October 2026.
- HCB206, a CD20 × SIRPα bispecific being developed for B-cell malignancies and autoimmune diseases, with planned oncology and autoimmune IND submissions subject to completion of the required development work.
- HCB301, a clinical-stage SIRPα × PD-L1 × TGFβ trispecific undergoing continued safety and development evaluation.
These programs demonstrate HanchorBio’s broader molecular engineering capabilities and provide additional opportunities for independent development and strategic partnerships.
About HanchorBio
HanchorBio Inc. (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation biologics for cancer and immune-mediated diseases through its proprietary FBDB™ platform. Powered by a multifunctional protein-engineering technology, its pipeline includes HCB101, HCB301, and HCB303. Operating across Taipei, the San Francisco Bay Area, and Shanghai, HanchorBio is committed to reimagining immunotherapy for patients worldwide.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s investigational products, clinical and regulatory development plans, potential therapeutic applications, future partnerships, combination strategies, and platform opportunities. These statements are subject to scientific, clinical, regulatory, commercial, and operational risks and uncertainties. Preliminary clinical findings may not predict results in subsequent controlled studies, and proposed combinations or collaborations may not achieve their intended objectives. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
HanchorBio Business Development Contact:
Email: [email protected]
Investor & Media Contact:
Email: [email protected]